Riccardo Pistelli

Prof. Riccardo Pistelli


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Therapeutic Advances in Chronic Disease
Verified
Journal Article
Open access
PDF file
ACAlessandro Celi
Alessandro Celi
MLManuela Latorre
Manuela Latorre
PPPierluigi Paggiaro
Pierluigi Paggiaro
RPRiccardo Pistelli
Riccardo Pistelli
Chronic obstructive pulmonary disease (COPD) has a 3-year mortality rate up to 37%, 2–6 times higher than the general population. We present evidence supporting pharmacological therapies to improve patient life expectancy, focusing on inhaled corticosteroids (ICSs) combined with long-acting bronchodilators (LABDs). A reduction in 3-year all-cause mortality (ACM) has been shown in patients with severe COPD treated with fluticasone propionate (an ICS) and salmeterol [long-acting beta-agonist (LABA)], compared with placebo. An observational study of elderly patients with severe COPD and multiple comorbidities suggested ICS+LABD reduce ACM compared with LABD monotherapy. Patients with symptomatic COPD at risk of exacerbations saw a mortality benefit with the ICS/long-acting muscarinic antagonist (LAMA)/LABA combinations fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) or budesonide/glycopyrrolate/formoterol (BUD/GLY/FOR) versus UMEC/VI or GLY/FOR (LAMA/LABA combinations) in the IMPACT and ETHOS trials, respectively. Reduced risk of mortality may be due to modulation of airway inflammation, thereby reducing activation of proinflammatory mediators in the peripheral circulation. Importantly, estimated annual risk reduction for ACM with ICS/LAMA/LABA combinations in patients with COPD is of the same order of magnitude as for statins (patients with coronary disease) and angiotensin-converting enzyme inhibitors (patients with vascular disease). Based on the current data, the pharmacological treatment of COPD appears not only able to improve symptoms and reduce the frequency of exacerbations but is also very promising in improving patient prognosis in the long term.

1 April 2020 in Pulmonary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
SCSilvia Calabria
Silvia Calabria
GRGiulia Ronconi
Giulia Ronconi
LDLetizia Dondi
Letizia Dondi
CPCarlo Piccinni
Carlo Piccinni
APAntonella Pedrini
Antonella Pedrini
NMNello Martini
Nello Martini

12 March 2026 in Exploration of asthma & allergy
Verified
Journal Article
Open access
PDF file
RPRiccardo Pistelli
Riccardo Pistelli
DVDeborah Vannucci
Deborah Vannucci
FAFabio Arpinelli
Fabio Arpinelli
CDCorrado D’ANdria
Corrado D’ANdria
Giorgio Walter CanonicaGiorgio Walter Canonica
Giorgio Walter Canonica
APPaRENT2 was a multi-country, cross-sectional, online survey of patients with asthma and physicians conducted in five countries (Argentina, Brazil, France, Mexico, and Italy), aimed at assessing physicians’ and patients’ preferred treatment strategies and goals. Education level, age, and place of residence differed between European and Latin American patients; furthermore, most Italian doctors worked within the Public Health Service. For the purpose of identifying the critical issues in the management of asthma in Italy, the data were analysed in greater detail, comparing those collected in Italy with those from Latin American countries and those provided by Italian patients and doctors. The data are reported as frequencies or means. The differences found in comparing data were not analysed for statistical significance, given the absence of any a priori hypothesis in the original paper. The Italian results were consistently within the range of the Latin American countries’ results. In Italy, despite the physicians’ prioritization of symptom control, many patients had poor asthma control but gave a surprisingly optimistic evaluation of their disease, given the high frequency of symptoms and limitations in everyday life. Physicians and patients had quite different evaluations of symptoms and outcomes of asthma. Finally, the combination of ICS/LABA with SABA as needed was the preferred treatment compared with the maintenance and reliever therapy (MART) strategy, suggested as preferential in the Global Initiative for Asthma (GINA) document. In conclusion, the absence of shared assessments and expectations between doctors and patients appears to be the primary issue to address in order to improve asthma treatment in Italy.

13 September 2011 in ISEE Conference Abstracts
Verified
Journal Article
Closed access
AVAna M. Vicedo-Cabrera
Ana M. Vicedo-Cabrera
DCDolores Catelan
Dolores Catelan
FRFranca Rusconi
Franca Rusconi
RPRiccardo Pistelli
Riccardo Pistelli
FBFabio Barbone
Fabio Barbone
ABAnnibale Biggeri
Annibale Biggeri
Environmental Health Perspectives is an Open Access journal published by the National Institute of Environmental Health Sciences. Environmental Health Perspectives is an Open Access journal published by the National Institute of Environmental Health Sciences.